[go: up one dir, main page]

BR9505980A - Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso - Google Patents

Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso

Info

Publication number
BR9505980A
BR9505980A BR9505980A BR9505980A BR9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
amino acid
production
pharmaceutical composition
acid sequences
Prior art date
Application number
BR9505980A
Other languages
English (en)
Other versions
BR9505980B1 (pt
Inventor
Francesc Mitjans
Jaume Piulats
Elisabet Rosell
Jaume Adan
Simon Goodman
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9505980(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9505980A publication Critical patent/BR9505980A/pt
Publication of BR9505980B1 publication Critical patent/BR9505980B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI9505980-6A 1994-12-20 1995-12-20 fragmento de anticorpo monoclonal bivalente, bem como composiÇço farmacÊutica compreendendo o mesmo. BR9505980B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (2)

Publication Number Publication Date
BR9505980A true BR9505980A (pt) 1997-12-23
BR9505980B1 BR9505980B1 (pt) 2010-02-23

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9505980-6A BR9505980B1 (pt) 1994-12-20 1995-12-20 fragmento de anticorpo monoclonal bivalente, bem como composiÇço farmacÊutica compreendendo o mesmo.

Country Status (26)

Country Link
US (1) US5985278A (pt)
EP (1) EP0719859B1 (pt)
JP (1) JP3898245B2 (pt)
KR (1) KR100450368B1 (pt)
CN (1) CN1117763C (pt)
AR (1) AR001778A1 (pt)
AT (1) ATE244306T1 (pt)
AU (1) AU710234B2 (pt)
BR (1) BR9505980B1 (pt)
CA (1) CA2165573C (pt)
CO (1) CO4480042A1 (pt)
CZ (1) CZ290477B6 (pt)
DE (1) DE69531187T2 (pt)
DK (1) DK0719859T3 (pt)
ES (1) ES2202336T3 (pt)
FI (1) FI118536B (pt)
HU (1) HU221061B1 (pt)
NO (1) NO321186B1 (pt)
PL (1) PL182961B1 (pt)
PT (1) PT719859E (pt)
RU (1) RU2205223C2 (pt)
SI (1) SI0719859T1 (pt)
SK (1) SK284932B6 (pt)
TR (1) TR199501614A2 (pt)
UA (1) UA40621C2 (pt)
ZA (1) ZA9510806B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
DE69840113D1 (de) * 1997-08-08 2008-11-20 Univ California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
DE69930723T2 (de) * 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
EP1372720A4 (en) * 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
EP1414491A4 (en) 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US20090220504A1 (en) * 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2851064A3 (en) 2006-07-11 2015-08-05 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
SI2068889T1 (sl) 2006-08-10 2020-03-31 Roy C. Levitt Anakinra za uporabo pri zdravljenju sindroma bronchiolitisa obliteransa
WO2008141274A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha v immunoliposome composition, methods and uses
WO2008141276A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha-v immunoliposome composition, methods and uses
BRPI0815567B8 (pt) * 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
HRP20160308T1 (hr) 2007-09-26 2016-04-22 Genentech, Inc. Nova protutijela
ES2440565T3 (es) 2008-12-23 2014-01-29 Merck Patent Gmbh Biomarcadores para inhibidores con actividad anti-angiogénica
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
BR112012011268A2 (pt) 2009-11-13 2019-09-24 Merck Patent Gmbh anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
SG183356A1 (en) * 2010-02-18 2012-09-27 Univ California INTEGRIN aVß8 NEUTRALIZING ANTIBODY
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
JP6088488B2 (ja) 2011-04-21 2017-03-01 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
JP6093360B2 (ja) * 2011-08-17 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンα−ｖβ−８と結合する抗体
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10022453B2 (en) 2013-12-23 2018-07-17 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
AU2015317411A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
EP4406606A3 (de) 2015-06-22 2024-10-09 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g
JP2018528161A (ja) 2015-06-23 2018-09-27 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤との部位特異的均一複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
EP3867276A1 (en) 2018-10-19 2021-08-25 Merck Patent GmbH Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
US20220195052A1 (en) * 2019-04-08 2022-06-23 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
CA3163339A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
US20240158510A1 (en) * 2021-03-09 2024-05-16 The Governing Council Of The University Of Toronto Antibodies against integrin heterodimers and uses thereof
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
ATE244306T1 (de) 2003-07-15
RU2205223C2 (ru) 2003-05-27
CZ328895A3 (en) 1996-09-11
NO955167D0 (no) 1995-12-19
FI118536B (fi) 2007-12-14
CA2165573C (en) 2011-03-29
UA40621C2 (uk) 2001-08-15
SI0719859T1 (en) 2003-12-31
CN1139115A (zh) 1997-01-01
NO321186B1 (no) 2006-04-03
KR100450368B1 (ko) 2005-01-31
JP3898245B2 (ja) 2007-03-28
JPH08231597A (ja) 1996-09-10
ES2202336T3 (es) 2004-04-01
SK159295A3 (en) 1996-07-03
DK0719859T3 (da) 2003-10-20
TR199501614A2 (tr) 1996-07-21
PL182961B1 (pl) 2002-05-31
AR001778A1 (es) 1997-12-10
EP0719859B1 (en) 2003-07-02
PL311926A1 (en) 1996-06-24
CA2165573A1 (en) 1996-06-21
HUT74828A (en) 1997-02-28
FI956112A0 (fi) 1995-12-19
HU221061B1 (hu) 2002-07-29
KR960022562A (ko) 1996-07-18
DE69531187D1 (de) 2003-08-07
CN1117763C (zh) 2003-08-13
PT719859E (pt) 2003-11-28
SK284932B6 (sk) 2006-02-02
US5985278A (en) 1999-11-16
CZ290477B6 (cs) 2002-07-17
FI956112L (fi) 1996-06-21
HU9503638D0 (en) 1996-02-28
EP0719859A1 (en) 1996-07-03
CO4480042A1 (es) 1997-07-09
DE69531187T2 (de) 2004-04-22
AU710234B2 (en) 1999-09-16
BR9505980B1 (pt) 2010-02-23
ZA9510806B (en) 1996-05-30
AU4042195A (en) 1996-06-27
NO955167L (no) 1996-06-21

Similar Documents

Publication Publication Date Title
BR9505980A (pt) Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso
BR9606706A (pt) Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
BR8906988A (pt) Tetrapiptidio,peptidio,composicao farmaceutica,processo para uso de peptidio e reagente para diagnostico
BR9600993A (pt) Acidos fosfonomonoéster nucléicos processo para sua preparação e seu uso
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
BR9605354A (pt) Composto composição farmacêutica processo para a produção do composto e uso
BR9608638A (pt) Processo e composição farmacêutica para o tratamento seletivo do crescimento e diferenciação de células e composto
PT866876E (pt) Processo para a preparacao de proteinas recombinantes em e. coli por fermentacao a elevada densidade celular
DE69839808D1 (de) Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
DE69841102D1 (de) Monoklonaler antikörper gegen ein prion protein und dessen verwendung zum nachweis von prionen
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
BR9607721A (pt) Processo para preparar compostos ciclo-hexapeptídeo
BR9402424A (pt) Compostos apresentando grupos amino terciário, processo para a sua preparação e sua utilização
BR9601275A (pt) Compostos processo para sua preparação medicamentos preparação farmacêutica processo para sua produção e uso
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
FI874252L (fi) Monoklonaalinen paratooppinen molekyyli ja sitä erittävä hybridooma käytettäviksi apolipoproteiini A-I:n määrittämiseen
BR9610892A (pt) Processo para produzir produtos de polieteramina composto de polieteramina composição de combustível e aplicação de um composto de polieteramina
PT92886A (pt) Processo para a preparacao de um peptido de sinal e para a secrecao de peptidos em escherichia coli por meio desse peptido de sinal
BR9407874A (pt) Proteína purificada de mamiferos designada por mitosina fragmento biologicamente ativo proteina purificada de mamiferos molécula isolada de ácido nucléico vetor de expressao sistema de vetor-hospedeiro para produçao de mitosina anticorpo antimitosina e processo para produçao de mitosina
BR8501366A (pt) Borracha de copolimero,processo para sua producao,composicao de borracha e mangueira para combustivel
ID1001B (id) Proses dan alat untuk fermentasi asam amino
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061586/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132267-10.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, MERIAL, MONSANTO TECHNOLAGY LLC.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130005158, DE 21/10/2013

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061586/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL PROCESSO NO 2013.51.01.132267-0 AUTOR INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU(S): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, MERIAL E MONSANTO TECHNOLOGY LLC DECISAO: DIANTE DE TODO O EXPOSTO, HOMOLOGO OS ACORDOS RELATIVOS AS PI9505980-6, PI9603377-0 E PI9609387-0, PARA QUE SE PRODUZAM OS EFEITOS LEGAIS E DECLARO EXTINTO O PROCESSO, COM RESOLUCAO DO MERITO, NOS TERMOS DO ART 269, INCISO III, DO CODIGO DE PROCESSO CIVIL, COM RELACAO AS CORRES MONSANTO E MERCK PATENT GMBH.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 38/00 (2006.0

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.061586/2013-01 31A VARA FEDERAL DO RIO DE JANEIRO NUP: 00408.031526/2020-19 (REF. 0132267-10.2013.4.02.5101) AUTOR: INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL REU: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG E OUTROS DECISAO: TRANSITO EM JULGADO EM 15.05.2020, DO ACORDAO FAVORAVEL AO INPI, QUE DEU PROVIMENTO A SUA APELACAO, EM PROCESSO QUE DISCUTE O PRAZO DE VALIDADE DAS PATENTES MAILBOX.